{
    "root": "de30798e-1b11-4835-a0ce-a2c8293f930a",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Levetiracetam",
    "value": "20250305",
    "ingredients": [
        {
            "name": "LEVETIRACETAM",
            "code": "44YRR34555"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "POVIDONE K30",
            "code": "U725QWY32X"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "HYPROMELLOSE 2910 (3 MPA.S)",
            "code": "0VUT3PMY82"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "POLYETHYLENE GLYCOL 4000",
            "code": "4R4HFI6D95"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "FD&C BLUE NO. 2 ALUMINUM LAKE",
            "code": "4AQJ3LG584"
        },
        {
            "name": "INDIGOTINDISULFONATE SODIUM",
            "code": "D3741U8K7L"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        }
    ],
    "indications": "levetiracetam indicated treatment partial-onset seizures patients 1 month age older ( 1.1 ) levetiracetam indicated adjunctive therapy treatment : \u2022 myoclonic seizures patients 12 years age older juvenile myoclonic epilepsy ( 1.2 ) \u2022 primary generalized tonic-clonic seizures patients 6 years age older idiopathic generalized epilepsy ( 1.3 )",
    "contraindications": "\u2022 oral solution pediatric patients body weight \u2264 20 kg ( 2.1 ) \u2022 pediatric patients , weight-based dosing oral solution calibrated measuring device ( household teaspoon tablespoon ) ( 2.1 ) partial-onset seizures ( monotherapy adjunctive therapy ) \u2022 1 month < 6 months : 7 mg/kg twice daily ; increase 7 mg/kg twice daily every 2 weeks recommended dose 21 mg/kg twice daily ( 2.2 ) \u2022 6 months < 4 years : 10 mg/kg twice daily ; increase 10 mg/kg twice daily every 2 weeks recommended dose 25 mg/kg twice daily ( 2.2 ) \u2022 4 years < 16 years : 10 mg/kg twice daily ; increase 10 mg/kg twice daily every 2 weeks recommended dose 30 mg/kg twice daily ( 2.2 ) \u2022 adults 16 years older : 500 mg twice daily ; increase 500 mg twice daily every 2 weeks recommended dose 1500 mg twice daily ( 2.2 ) myoclonic seizures adults pediatric patients 12 years older \u2022 500 mg twice daily ; increase 500 mg twice daily every 2 weeks recommended dose 1500 mg twice daily ( 2.3 ) primary generalized tonic-clonic seizures \u2022 6 years < 16 years : 10 mg/kg twice daily , increase increments 10 mg/kg twice daily every 2 weeks recommended dose 30 mg/kg twice daily ( 2.4 ) \u2022 adults 16 years older : 500 mg twice daily , increase 500 mg twice daily every 2 weeks recommended dose 1500 mg twice daily ( 2.4 ) adult patients impaired renal function \u2022 dose adjustment recommended , based patient \u2019 estimated creatinine clearance ( 2.5 , 8.6 )",
    "warningsAndPrecautions": null,
    "adverseReactions": "levetiracetam tablets contraindicated patients hypersensitivity levetiracetam . included anaphylaxis angioedema [ ( 5.4 ) ] .",
    "indications_original": "Levetiracetam is indicated for\u00a0the treatment of partial-onset seizures in patients 1 month of age and older (1.1) Levetiracetam is indicated for adjunctive therapy for the treatment of: \u2022 Myoclonic seizures in patients\u00a012 years of age and older with juvenile myoclonic epilepsy (1.2) \u2022 Primary generalized tonic-clonic seizures in patients 6 years of age and older with idiopathic generalized epilepsy (1.3)",
    "contraindications_original": "\u2022 Use the oral solution for pediatric patients with body weight \u2264 20 kg ( 2.1 ) \u2022 For pediatric patients, use weight-based dosing for the oral solution with a calibrated measuring device (not a household teaspoon or tablespoon) ( 2.1 ) Partial-Onset Seizures (monotherapy or adjunctive therapy) \u2022 1 Month to < 6 Months:\u00a0 7 mg/kg twice daily; increase by 7 mg/kg twice daily every 2 weeks to recommended dose of 21 mg/kg twice daily ( 2.2 ) \u2022 6 Months to < 4 Years:\u00a0 10 mg/kg twice daily; increase by 10 mg/kg twice daily every 2 weeks to recommended dose of 25 mg/kg twice daily ( 2.2 ) \u2022 4 Years to < 16 Years: 10 mg/kg twice daily; increase by 10 mg/kg twice daily every 2 weeks to recommended dose of 30 mg/kg twice daily ( 2.2 ) \u2022 Adults 16 Years and Older:\u00a0 500 mg twice daily; increase by 500 mg twice daily every 2 weeks to a recommended dose of 1500 mg twice daily ( 2.2 ) Myoclonic Seizures in Adults and Pediatric Patients 12 Years and Older \u2022 500 mg twice daily; increase by 500 mg twice daily every 2 weeks to recommended dose of 1500 mg twice daily ( 2.3 ) Primary Generalized Tonic-Clonic Seizures \u2022 6 Years to < 16 Years: 10 mg/kg twice daily, increase in increments of 10 mg/kg twice daily every 2 weeks to recommended dose of 30 mg/kg twice daily ( 2.4 ) \u2022 Adults 16 Years and Older:\u00a0 500 mg twice daily, increase by 500 mg twice daily every 2 weeks to recommended dose of 1500 mg twice daily ( 2.4 ) Adult Patients with Impaired Renal Function \u2022 Dose adjustment is recommended, based on the patient\u2019s estimated creatinine clearance ( 2.5 , 8.6 )",
    "adverseReactions_original": "Levetiracetam tablets are contraindicated in patients with a hypersensitivity to levetiracetam. Reactions have included anaphylaxis and angioedema [see Warnings and Precautions (5.4)]."
}